25 publications
Name | Date | Type | Actions |
---|---|---|---|
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
Public releases | ||
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
Public releases | ||
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
Public releases | ||
Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées. |
Public releases | ||
Vétoquinol strengthens its position in Europe with the acquisition of Ascor Chimici in Italy Vétoquinol announces the signing of a contract to acquire 100 percent of the shares of Ascor Chimici S.r.l, which will take effect on 1 December 2008. |
Public releases | ||
Revenues for the first nine months of 2008 Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis). |
Public releases | ||
Vétoquinol: 2008 results expected to be in line with objectives At its meeting of 25 August 2008, the Board of Directors of Vétoquinol S.A. reviewed the Group’s operations and approved the financial statements for |
Public releases | ||
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
Public releases | ||
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
Public releases | ||
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
Public releases |